Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trellis and OMT Announce Therapeutic Antibody Discovery Collaboration

Published: Tuesday, October 09, 2012
Last Updated: Tuesday, October 09, 2012
Bookmark and Share
Companies will join forces to generate human antibodies against therapeutic targets using OMT’s OmniRat™ platform.

Trellis Bioscience LLC (Trellis) and Open Monoclonal Technology, Inc. (OMT) have announced a new collaboration where the companies will join forces to generate human antibodies against therapeutic targets identified by Trellis and its partners using OMT’s OmniRat™ platform.

Trellis will apply its CellSpot™ antibody screening technology to libraries of OmniRat-generated B cells to discover high affinity, ultra rare antibodies with precisely defined specificity.

Trellis will advance and partner each program and share the deal economics with OMT depending on the stage of development.

Stote Ellsworth, Trellis CEO and President, said: “Trellis’ CellSpot platform has shown in four consecutive programs the unique ability to mine rare, best-in-class therapeutic antibodies directly from human blood. In addition to our native human approach, the collaboration with OMT will leverage Trellis’ powerful multiplexed screening in the context of antibody libraries generated with the OmniRat platform. This will allow Trellis to expand into new therapeutic areas and expand its commercial opportunities, particularly in the field of cancer.”

Dr. Roland Buelow, OMT CEO and Founder, continued: "We are pleased to collaborate with Trellis to capture the synergies of our complementary antibody discovery technologies. This collaboration further illustrates OMT’s ability to partner with a range of companies to produce human therapeutic antibodies.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

WuXi PharmaTech and OMT Announce OmniRat™ Antibody Collaboration
OmniRat™ technology allows WuXi to expand its service offerings in discovery of fully human antibodies.
Thursday, January 17, 2013
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Vortex Ring Freezing Applications
Accidental lab discovery could aid cell delivery and cell-free protein production.
Examining Immune Memory
Researchers investigate the 'storage/research for the future' functions of antibodies and understanding of B cells.
Expanding the Stable of Workhorse Yeasts
New genome sequences target the next generation of yeasts with improved biotechnology uses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Blocking the Migration of Cancer Cells to Destroy Them
Scientists in Geneva developed an antibody able to fight off lymphomas.
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!